Helicobacter pylori infection
Conditions
Interventions
Group A:14-day oral medication therapy: Vonoprazan 20mg twice a day, amoxicillin 1000mg three times a day, berberine hydrochloride 500mg twice a day
Group B:14-day oral medication regimen: Vonoprazan 20mg twice a day, amoxicillin 1000mg three times a day
Group C:14-day oral medication regimen: rabeprazole 10mg twice a day, bismuth pectin granules 300mg twice a day, amoxicillin 1000mg twice a day, furazolidone 100mg twice a day
Sponsors
the Ninth People's Hospital of Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Select patients who have failed in eradicated Hp (previous treatment regimens include but are not limited to clarithromycin, metronidazole and/or amoxicillin, etc.) and have been diagnosed as Hp positive after examination aging 18 to 80 years old who visited our hospital. The diagnosis of Hp requires at least one of the following three tests: histopathological examination, 13C urea breath test, or 14C urea breath test. (2) Meet the indications for Hp eradication (as per the "Fifth National Consensus Report on the Management of Helicobacter pylori Infection"). (3) Those who have not used antibiotics, bismuth agents, acid suppressants or other drugs in the 8 weeks prior to treatment. (4) The time interval since the last anti-Hp treatment should be at least half a year. (5) Clearly understand and voluntarily participate in this research, and have the informed consent form signed by themselves or their family members.
Exclusion criteria
Exclusion criteria: (1) Initial treatment patients with Hp infection; (2) The subjects have undergone surgeries such as subtotal gastrectomy or total gastrectomy that may affect gastric acid secretion or drug absorption; (3) Antibiotics, bismuth agents and traditional Chinese medicines with antibacterial activity were taken 4 weeks before treatment, and drugs such as P-CAB, PPI and H2 receptor antagonists were taken 2 weeks before treatment; (4) Those with severe insufficiency of heart, lung, kidney or liver function and low immunity; (5) Pregnant and lactating patients; (6) Those with mental illnesses or communication disorders; (7) Patients who are allergic to the drugs used in the eradication therapy; (8) Patients with a history of gastrointestinal malignancies; (9) Those suffering from hemolytic anemia or hereditary glucose-6-phosphate dehydrogenase deficiency (favism); (9) The guardian or the patient refuses to be enrolled in the group; (10) Those without legal capacity or with poor self-awareness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate of Helicobacter pylori;Incidence of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate of gastrointestinal symptoms;The changes in the abundance of intestinal flora;Medication compliance rate;Drug expenses of each group; | — |
Countries
China
Contacts
Public ContactLiu Zhang
the Ninth People's Hospital of Chongqing
Outcome results
None listed